NVAX H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Novavax on Monday, setting a price target of $294, which is approximately 45.58% above the present share price of $201.95

NVAX Европейское агентство по лекарственным средствам рекомендовало выдать условное разрешение на продажу вакцины Novavax против COVID-19 (также известной как NVX-CoV2373) для профилактики COVID-19 у людей в возрасте от 18 лет и старше https://www.ema.europa.eu/en/news/ema-recommends-nuvaxovid-authorisation-eu?s=09

NVAX has $15 billion+ sales in 2022 at $16 billion market cap. BioNTECH market cap is $70 billion. NVAX needs to be at $920 to get a market cap of $70 billion. #ema approval is coming next week #uk approval is coming in December #india approval is coming in January #fda approval is coming in January #japan approval is coming in January #korea approval is coming in January #nvax flu vaccine is coming in July of 2022